<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_prodigiosin" title="Targeted Delivery Prodigiosin to Choriocarcinoma by Peptide-Guided Dendrigraft Poly-l-lysines Nanoparticles" shortTitle="prodigiosin" author="Kai Zhao, Dan Li, Guogang Cheng, Baozhen Zhang, Jinyu Han, Jie Chen, Baobei Wang, Mengxia Li, Tianxia Xiao, Jian Zhang, Dongpo Zhou, Zheng Jin, Xiujun Fan" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/1422-0067/20/21/5458/htm" speakerList="none" speakerCount="0">
<head>
<s type="frag">
1.	LS	1.
Introduction	NN	introduction
</s>
</head>
<p>
<s type="decl">
Cancer	NNP	Cancer
has	VBZ	have
been	VBN	be
a	DT	a
major	JJ	major
threat	NN	threat
to	IN	to
human	JJ	human
health	NN	health
in	IN	in
recent	JJ	recent
years	NNS	year
.	.	.
</s>
<s type="decl">
In	IN	in
the	DT	the
past	JJ	past
forty	CD	40
years	NNS	year
,	,	,
even	RB	even
though	IN	though
great	JJ	great
efforts	NNS	effort
have	VBP	have
been	VBN	be
made	VBN	make
,	,	,
there	EX	there
is	VBZ	be
still	RB	still
much	JJ	much
to	TO	to
be	VB	be
done	VBN	do
before	IN	before
a	DT	a
safe	JJ	safe
therapy	NN	therapy
is	VBZ	be
achieved	VBN	achieve
.	.	.
</s>
<s type="decl">
Currently	RB	currently
,	,	,
chemotherapy	NN	chemotherapy
and	CC	and
radiotherapy	NN	radiotherapy
are	VBP	be
still	RB	still
the	DT	the
main	JJ	main
therapeutic	JJ	therapeutic
methods	NNS	method
for	IN	for
cancer	NN	cancer
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
most	JJS	most
of	IN	of
the	DT	the
anticancer	NN	anticancer
drugs	NNS	drug
have	VBP	have
toxic	JJ	toxic
side	NN	side
effects	NNS	effect
.	.	.
</s>
<s type="decl">
Therefore	RB	therefore
,	,	,
it	PRP	it
is	VBZ	be
critical	JJ	critical
to	TO	to
develop	VB	develop
novel	NN	novel
anticancer	NN	anticancer
drugs	NNS	drug
that	WDT	that
have	VBP	have
no	DT	no
toxic	JJ	toxic
side	NN	side
effects	NNS	effect
on	IN	on
other	JJ	other
tissues	NNS	tissue
or	CC	or
organs	NNS	organ
in	IN	in
vivo	NN	vivo
,	,	,
and	CC	and
only	RB	only
target	VBP	target
the	DT	the
lesion	NN	lesion
area	NN	area
.	.	.
</s>
<s type="decl">
Compared	VBN	compare
with	IN	with
traditional	JJ	traditional
chemotherapeutic	JJ	chemotherapeutic
drugs	NNS	drug
,	,	,
the	DT	the
nano-anticancer	JJ	nano-anticancer
drug	NN	drug
therapy	NN	therapy
has	VBZ	have
potential	JJ	potential
application	NN	application
prospects	NNS	prospect
in	IN	in
curing	VBG	cure
cancer	NN	cancer
diseases	NNS	disease
.	.	.
</s>
</p>
<p>
<s type="decl">
One	CD	one
of	IN	of
the	DT	the
major	JJ	major
concerns	NNS	concern
about	IN	about
the	DT	the
nano-anticancer	NN	nano-anticancer
drugs	NNS	drug
is	VBZ	be
the	DT	the
drug-delivery	JJ	drug-delivery
vector	NN	vector
.	.	.
</s>
<s type="sub">
The	DT	the
ideal	JJ	ideal
delivery	NN	delivery
vector	NN	vector
should	MD	should
possess	VB	possess
such	JJ	such
characteristics	NNS	characteristic
as	IN	as
a	DT	a
high	JJ	high
drug-loading	NN	drug-loading
capacity	NN	capacity
,	,	,
low	JJ	low
immunogenicity	NN	immunogenicity
,	,	,
low	JJ	low
toxicity	NN	toxicity
,	,	,
better	JJR	good
shelf-life	NN	shelf-life
,	,	,
and	CC	and
water	NN	water
solubility	NN	solubility
,	,	,
and	CC	and
it	PRP	it
should	MD	should
have	VB	have
the	DT	the
potential	NN	potential
to	TO	to
be	VB	be
further	RBR	far
modified	VBN	modify
.	.	.
</s>
<s type="decl">
Synthetic	JJ	Synthetic
polymers	NNS	polymer
,	,	,
such	JJ	such
as	IN	as
,	,	,
chitosan	NN	chitosan
,	,	,
polyetherimide	NN	polyetherimide
(	-LRB-	(
PEI	NNP	PEI
)	-RRB-	)
,	,	,
poly(lactic-co-glycolic	NNP	poly(lactic-co-glycolic
acid	NN	acid
)	-RRB-	)
(	-LRB-	(
PLGA	NNP	PLGA
)	-RRB-	)
,	,	,
polyamidoamine	NN	polyamidoamine
(	-LRB-	(
PAMAM	NNP	PamaM
)	-RRB-	)
,	,	,
and	CC	and
poly-l-lactic	NN	poly-l-lactic
acid	NN	acid
(	-LRB-	(
PLA	NNP	PLA
)	-RRB-	)
have	VBP	have
been	VBN	be
widely	RB	widely
used	VBN	use
in	IN	in
gene-	NN	gene-
and	CC	and
drug-delivery	NN	drug-delivery
systems	NNS	system
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
stability	NN	stability
of	IN	of
sustained-release	JJ	sustained-release
formulations	NNS	formulation
in	IN	in
aqueous	JJ	aqueous
solution	NN	solution
,	,	,
long	JJ	long
delivery	NN	delivery
times	NNS	time
,	,	,
and	CC	and
low	JJ	low
delivery	NN	delivery
efficiency	NN	efficiency
are	VBP	be
only	RB	only
a	DT	a
small	JJ	small
part	NN	part
of	IN	of
the	DT	the
challenges	NNS	challenge
highlighted	VBN	highlight
by	IN	by
researchers	NNS	researcher
.	.	.
</s>
<s type="frag">
Dendrigraft	NNP	Dendrigraft
</s>
<s type="decl">
poly-l-lysines	NNS	poly-l-lysine
(	-LRB-	(
DGL	NNP	DGL
)	-RRB-	)
have	VBP	have
emerged	VBN	emerge
as	IN	as
a	DT	a
new	JJ	new
kind	NN	kind
of	IN	of
synthetic	JJ	synthetic
polymer	NN	polymer
consisting	VBG	consist
of	IN	of
lysine	NN	lysine
and	CC	and
have	VBP	have
been	VBN	be
employed	VBN	employ
as	IN	as
drug-	NN	drug-
or	CC	or
gene-delivery	NN	gene-delivery
carriers	NNS	carry
,	,	,
due	JJ	due
to	IN	to
their	PRP$	their
biodegradability	NN	biodegradability
and	CC	and
rich	JJ	rich
external	JJ	external
amino	NN	amino
groups	NNS	group
that	WDT	that
can	MD	can
encapsulate	VB	encapsulate
drugs	NNS	drug
by	IN	by
the	DT	the
emulsion	NN	emulsion
crosslinking	NN	crosslinking
method	NN	method
or	CC	or
plasmid	NN	plasmid
DNA	NN	DNA
through	IN	through
electric	JJ	electric
interactions	NNS	interaction
.	.	.
</s>
<s type="decl">
Besides	IN	besides
their	PRP$	their
biodegradability	NN	biodegradability
,	,	,
they	PRP	they
can	MD	can
also	RB	also
be	VB	be
modified	VBN	modify
with	IN	with
targeting	VBG	target
ligands	NNS	ligand
and	CC	and
polyethylene	NN	polyethylene
glycol	NN	glycol
(	-LRB-	(
PEG	NN	PEG
)	-RRB-	)
,	,	,
thereby	RB	thereby
rendering	VBG	render
vectors	NNS	vector
with	IN	with
targeting	NN	targeting
properties	NNS	property
and	CC	and
long	JJ	long
circulation	NN	circulation
.	.	.
</s>
<s type="decl">
As	RB	as
yet	RB	yet
,	,	,
there	EX	there
are	VBP	be
only	RB	only
a	DT	a
few	JJ	few
ways	NNS	way
available	JJ	available
for	IN	for
targeted	VBN	target
delivery	NN	delivery
of	IN	of
anticancer	NN	anticancer
drugs	NNS	drug
.	.	.
</s>
<s type="decl">
Recently	RB	recently
,	,	,
a	DT	a
report	NN	report
showed	VBD	show
that	IN	that
VAR2CSA	NNP	VAR2CSA
,	,	,
which	WDT	which
is	VBZ	be
exposed	VBN	expose
on	IN	on
the	DT	the
membrane	NN	membrane
of	IN	of
<hi rend="italic">
Plasmodium	NNP	Plasmodium
falciparum	NN	falciparum
</hi>
infected	VBN	infect
red	JJ	red
blood	NN	blood
cells	NNS	cell
(	-LRB-	(
iRBC	NNP	IRBC
)	-RRB-	)
,	,	,
could	MD	could
bind	VB	bind
to	IN	to
90	CD	90
%	NN	%
of	IN	of
tumors	NNS	tumor
,	,	,
which	WDT	which
was	VBD	be
verified	VBN	verify
by	IN	by
running	VBG	run
immunohistochemistry	NN	immunohistochemistry
on	IN	on
a	DT	a
tumor-tissue	JJ	tumor-tissue
array	NN	array
.	.	.
</s>
<s type="decl">
Therefore	RB	therefore
,	,	,
VAR2CSA	NNP	VAR2CSA
is	VBZ	be
becoming	VBG	become
an	DT	a
attractive	JJ	attractive
target	NN	target
for	IN	for
anticancer	NN	anticancer
drugs	NNS	drug
â€™	POS	's
development	NN	development
.	.	.
</s>
<s type="decl">
<hi rend="italic">
P.	NNP	P.
falciparum	NN	falciparum
</hi>
infection	NN	infection
during	IN	during
pregnancy	NN	pregnancy
results	VBZ	result
in	IN	in
the	DT	the
sequestration	NN	sequestration
of	IN	of
iRBC	NN	iRBC
in	IN	in
the	DT	the
placenta	NN	placenta
by	IN	by
adhering	VBG	adhere
to	IN	to
a	DT	a
distinct	JJ	distinct
type	NN	type
of	IN	of
chondroitin	NN	chondroitin
sulfate	NN	sulfate
A	NNP	A
(	-LRB-	(
CSA	NNP	CSA
)	-RRB-	)
exclusively	RB	exclusively
expressed	VBN	express
on	IN	on
trophoblast	NN	trophoblast
via	IN	via
VAR2CSA	NNP	VAR2CSA
.	.	.
</s>
<s type="decl">
Short	JJ	short
continuous	JJ	continuous
regions	NNS	region
of	IN	of
VAR2CSA	NNP	VAR2CSA
with	IN	with
affinity	NN	affinity
for	IN	for
multiple	JJ	multiple
types	NNS	type
of	IN	of
CSA	NNP	CSA
were	VBD	be
defined	VBN	define
.	.	.
</s>
<s type="decl">
A	DT	a
28	CD	28
amino	NN	amino
acids	NNS	acid
placenta	NN	placenta
CSA-binding	NNP	CSA-binding
peptide	NN	peptide
(	-LRB-	(
plCSA-BP	NNP	plCSA-BP
)	-RRB-	)
from	IN	from
the	DT	the
VAR2CSA	NNP	VAR2CSA
region	NN	region
was	VBD	be
recently	RB	recently
tested	VBN	test
as	IN	as
a	DT	a
guide	NN	guide
peptide	NN	peptide
for	IN	for
targeted	JJ	targeted
delivery	NN	delivery
of	IN	of
doxorubicin	NN	doxorubicin
to	IN	to
choriocarcinoma	NN	choriocarcinoma
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
whether	IN	whether
it	PRP	it
could	MD	could
be	VB	be
used	VBN	use
to	TO	to
modify	VB	modify
the	DT	the
DGL	NNP	DGL
and	CC	and
its	PRP$	its
bioactivity	NN	bioactivity
after	IN	after
the	DT	the
modification	NN	modification
was	VBD	be
not	RB	not
evaluated	VBN	evaluate
.	.	.
</s>
</p>
<p>
<s type="decl">
The	DT	the
immunosuppressive	JJ	immunosuppressive
,	,	,
antimalarial	JJ	antimalarial
,	,	,
and	CC	and
pro-cytotoxic	JJ	pro-cytotoxic
bacterial	JJ	bacterial
prodigiosin	NN	prodigiosin
was	VBD	be
recently	RB	recently
described	VBN	describe
as	IN	as
a	DT	a
potent	JJ	potent
antimetastatic	JJ	antimetastatic
and	CC	and
anticancer	JJ	anticancer
agent	NN	agent
.	.	.
</s>
<s type="decl">
It	PRP	it
can	MD	can
induce	VB	induce
apoptosis	NN	apoptosis
in	IN	in
a	DT	a
wide	JJ	wide
range	NN	range
of	IN	of
cancer	NN	cancer
cell	NN	cell
lines	NNS	line
,	,	,
including	VBG	include
hematopoietic	JJ	hematopoietic
cancer	NN	cancer
,	,	,
breast	NN	breast
cancer	NN	cancer
,	,	,
gastric	JJ	gastric
cancer	NN	cancer
,	,	,
colon	NN	colon
cancer	NN	cancer
,	,	,
lung	NN	lung
cancer	NN	cancer
,	,	,
and	CC	and
rat	NN	rat
hepatocellular	JJ	hepatocellular
carcinoma	NN	carcinoma
cell	NN	cell
lines	NNS	line
,	,	,
with	IN	with
no	DT	no
marked	JJ	marked
toxicity	NN	toxicity
in	IN	in
nonmalignant	JJ	nonmalignant
cells	NNS	cell
.	.	.
</s>
<s type="decl">
However	RB	however
,	,	,
prodigiosin	NN	prodigiosin
has	VBZ	have
not	RB	not
been	VBN	be
reported	VBN	report
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
choriocarcinoma	NN	choriocarcinoma
yet	RB	yet
.	.	.
</s>
<s type="decl">
It	PRP	it
is	VBZ	be
selective	JJ	selective
in	IN	in
promoting	VBG	promote
apoptosis	NN	apoptosis
of	IN	of
malignant	JJ	malignant
tumor	NN	tumor
cells	NNS	cell
,	,	,
rendering	VBG	render
prodigiosin	NN	prodigiosin
a	DT	a
promising	JJ	promising
anticancer	JJ	anticancer
agent	NN	agent
.	.	.
</s>
<s type="decl">
The	DT	the
antitumor	NN	antitumor
mechanism	NN	mechanism
of	IN	of
prodigiosin	NN	prodigiosin
is	VBZ	be
still	RB	still
unclear	JJ	unclear
,	,	,
especially	RB	especially
in	IN	in
regard	NN	regard
to	IN	to
newly	RB	newly
acquired	VBN	acquire
prodigiosin	NN	prodigiosin
produced	VBN	produce
by	IN	by
a	DT	a
small	JJ	small
number	NN	number
of	IN	of
microorganisms	NNS	microorganism
,	,	,
including	VBG	include
<hi rend="italic">
Serratia	NNP	Serratia
marcescens	NNS	marcescen
</hi>
and	CC	and
other	JJ	other
bacteria	NNS	bacteria
,	,	,
such	JJ	such
as	IN	as
<hi rend="italic">
Streptomyces	NNP	Streptomyces
griseoviridis	NN	griseoviridis
</hi>
,	,	,
<hi rend="italic">
Serratia	NNP	Serratia
</hi>
spp.	FW	spp.
,	,	,
<hi rend="italic">
Zooshikellarubidus	NNP	Zooshikellarubidus
,	,	,
Vibrio	NNP	Vibrio
</hi>
sp.	NN	sp.
,	,	,
<hi rend="italic">
Actinomycetes	NNP	Actinomycetes
</hi>
,	,	,
and	CC	and
<hi rend="italic">
Hahella	NNP	Hahella
chejuensis	NN	chejuensis
</hi>
.	.	.
</s>
<s type="frag">
Research	NN	research
on	IN	on
the	DT	the
mechanism	NN	mechanism
of	IN	of
bacterial	JJ	bacterial
origin	NN	origin
</s>
<s type="decl">
prodigiosin	NN	prodigiosin
is	VBZ	be
very	RB	very
important	JJ	important
for	IN	for
clinical	JJ	clinical
application	NN	application
and	CC	and
drug	NN	drug
development	NN	development
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
this	DT	this
study	NN	study
,	,	,
to	TO	to
develop	VB	develop
a	DT	a
new	JJ	new
type	NN	type
of	IN	of
targeted	VBN	target
drug	NN	drug
delivery	NN	delivery
carrier	NN	carrier
material	NN	material
and	CC	and
investigate	VB	investigate
the	DT	the
anticancer	JJ	anticancer
mechanism	NN	mechanism
of	IN	of
prodigiosin	NN	prodigiosin
,	,	,
we	PRP	we
first	RB	first
used	VBD	use
plCSA-BP	NNP	plCSA-BP
as	IN	as
a	DT	a
guide	NN	guide
peptide	NN	peptide
to	TO	to
coat	VB	coat
on	IN	on
the	DT	the
DGL	NNP	DGL
vector	NN	vector
for	IN	for
cancer-cell-targeted	JJ	cancer-cell-targeted
delivery	NN	delivery
of	IN	of
prodigiosin	NN	prodigiosin
produced	VBN	produce
from	IN	from
<hi rend="italic">
Serratia	NNP	Serratia
marcescens	NNS	marcescen
</hi>
subsp	NN	subsp
.	.	.
<hi rend="italic">
lawsoniana	NN	lawsoniana
</hi>
HDZK-BYSB107	NNP	HDZK-BYSB107
.	.	.
</s>
<s type="decl">
Then	RB	then
,	,	,
we	PRP	we
tested	VBD	test
the	DT	the
binding	NN	binding
ability	NN	ability
of	IN	of
the	DT	the
newly	RB	newly
developed	VBN	develop
DGL/CSA-PNPs	NNP	DGlrcSA-PNPs
and	CC	and
its	PRP$	its
anticancer	JJ	anticancer
effect	NN	effect
in	IN	in
vitro	NN	vitro
on	IN	on
a	DT	a
JEG3	NNP	JEG3
choriocarcinoma	NN	choriocarcinoma
cell	NN	cell
line	NN	line
and	CC	and
<hi rend="italic">
in	IN	in
vivo	NN	vivo
</hi>
on	IN	on
a	DT	a
tumor	NN	tumor
model	NN	model
,	,	,
respectively	RB	respectively
.	.	.
</s>
<s type="decl">
In	IN	in
addition	NN	addition
,	,	,
the	DT	the
mechanism	NN	mechanism
responsible	JJ	responsible
for	IN	for
the	DT	the
anticancer	NN	anticancer
effect	NN	effect
of	IN	of
targeted	VBN	target
nano-prodigiosin	NN	nano-prodigiosin
was	VBD	be
also	RB	also
investigated	VBN	investigate
.	.	.
</s>
<s type="decl">
Overall	RB	overall
,	,	,
these	DT	this
findings	NNS	finding
suggested	VBD	suggest
that	IN	that
the	DT	the
DGL/CSA	NNP	DGL/CSA
vector	NN	vector
is	VBZ	be
an	DT	a
excellent	JJ	excellent
cancer-specific-drug	JJ	cancer-specific-drug
delivery	NN	delivery
carrier	NN	carrier
,	,	,
which	WDT	which
has	VBZ	have
great	JJ	great
potential	NN	potential
as	IN	as
a	DT	a
novel	JJ	novel
delivery	NN	delivery
system	NN	system
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
cancer	NN	cancer
.	.	.
</s>
</p>
</text>